These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26917670)

  • 1. Two Unique Glioma Subtypes Revealed.
    Poh A
    Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
    Schittenhelm J; Mittelbronn M; Meyermann R; Melms A; Tatagiba M; Capper D
    Acta Neuropathol; 2011 Nov; 122(5):651-2. PubMed ID: 21983902
    [No Abstract]   [Full Text] [Related]  

  • 4. [IDH mutation on glioma].
    Mukasa A
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):937-40. PubMed ID: 21751529
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.
    Louis DN; Giannini C; Capper D; Paulus W; Figarella-Branger D; Lopes MB; Batchelor TT; Cairncross JG; van den Bent M; Wick W; Wesseling P
    Acta Neuropathol; 2018 Apr; 135(4):639-642. PubMed ID: 29497819
    [No Abstract]   [Full Text] [Related]  

  • 7. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Taylor JW; Chi AS; Cahill DP
    Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
    Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
    Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
    Anderson MD; Abel TW; Moots PL
    Neuro Oncol; 2013 Jul; 15(7):811-3. PubMed ID: 23737489
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas].
    Larsen CJ
    Bull Cancer; 2009 Jun; 96(6):641-2. PubMed ID: 19585679
    [No Abstract]   [Full Text] [Related]  

  • 13. Correspondence regarding: diagnostic utility of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009:68;1319-25.
    Wiwanitkit V
    J Neuropathol Exp Neurol; 2010 Mar; 69(3):320; author reply 320-1. PubMed ID: 20190607
    [No Abstract]   [Full Text] [Related]  

  • 14. Magnetic resonance metabolic imaging of glioma.
    Metellus P; Figarella-Branger D
    Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma IDH1 mutation patterns off the beaten track.
    Pusch S; Sahm F; Meyer J; Mittelbronn M; Hartmann C; von Deimling A
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):428-30. PubMed ID: 20874727
    [No Abstract]   [Full Text] [Related]  

  • 17. On high-risk, low-grade glioma: What distinguishes high from low?
    Geurts M; van den Bent MJ
    Cancer; 2019 Jan; 125(2):174-176. PubMed ID: 30512190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
    Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
    Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving genomic landscape of recurrent gliomas.
    Ampie L; Kusne Y; Sanai N
    World Neurosurg; 2015 May; 83(5):722-3. PubMed ID: 25765925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.